Search for: "BRISTOL-MYERS SQUIBB COMPANY" Results 81 - 100 of 351
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
28 Jun 2017, 8:34 am by Altman & Altman
Ability’s manufacturers, Otsuka and Bristol-Myers Squibb, are facing a growing number of lawsuits from patients who claim they couldn’t control the urge to gamble or over-eat, or that they developed hyper sexual behaviors. [read post]
27 Jun 2017, 8:00 am by The Editors
On June 19, 2017, the Supreme Court reinforced its narrow application of specific jurisdiction in mass tort proceedings in an 8-1 decision in Bristol-Myers Squibb Company v. [read post]
27 Jun 2017, 8:00 am by The Editors
On June 19, 2017, the Supreme Court reinforced its narrow application of specific jurisdiction in mass tort proceedings in an 8-1 decision in Bristol-Myers Squibb Company v. [read post]
26 Jun 2017, 3:34 am by Liz Dunshee
And tune in for our October 10 webcast – “E&S Disclosures: The In-House Perspective” – featuring experts from the Coca-Cola Company, Bristol-Myers Squibb, Apple & Clorox. [read post]
22 Jun 2017, 11:23 am by Michael J. Mueller
Bristol-Myers Squibb (“BMS”) objected to the exercise of personal jurisdiction over it with respect to the nonresident plaintiffs’ claims. [read post]
20 Jun 2017, 4:29 am by Edith Roberts
And in Bristol-Myers Squibb Co. v. [read post]
24 May 2017, 7:38 am by Robert Kraft
Bristol-Myers Squibb and Otsuka began marketing the drug in the US in 2002. [read post]
29 Apr 2017, 10:08 am by Dr. Shezad Malik
Wrendell Chester, from Texas, recently filed a personal injury and product liability lawsuit, against Bristol-Myers Squibb and AstraZeneca, the manufacturers of the drug. [read post]
12 Apr 2017, 2:22 pm by Tom Lamb
An Observational Study Compared Myocardial Infarction / Heart Attack Risks As Between The Use Of Newer Blood Thinners And The Use Of Warfarin   (Posted by Tom Lamb at DrugInjuryWatch.com)   In the US, there are currently four direct-acting oral anticoagulants (DOACs), a relatively new class of blood thinners, approved for the prevention of stroke in patients with atrial fibrillation (AF): Pradaxa (dabigatran) -- approved by FDA in 2010 -- Boehringer Ingelheim Pharmaceuticals Xarelto… [read post]